Dr. Reddy’s Laboratories (NYSE:RDY) Issues Quarterly Earnings Results

Dr. Reddy’s Laboratories (NYSE:RDY) posted its quarterly earnings results on Thursday. The company reported $0.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.19 by $0.01, Zacks reports. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%.

Dr. Reddy’s Laboratories Trading Down 5.2 %

RDY stock traded down $0.79 during mid-day trading on Thursday, reaching $14.31. The company’s stock had a trading volume of 635,237 shares, compared to its average volume of 2,210,501. The business’s 50 day moving average price is $14.87 and its 200 day moving average price is $15.54. Dr. Reddy’s Laboratories has a 12 month low of $13.61 and a 12 month high of $16.89. The company has a market cap of $11.94 billion, a price-to-earnings ratio of 22.85 and a beta of 0.51. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on RDY shares. StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a report on Friday, December 6th. Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a report on Thursday, December 19th. Finally, Barclays reduced their price objective on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th.

Dr. Reddy’s Laboratories Company Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.